Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2009 Jun;23(3):431-46, vii-viii. doi: 10.1016/j.hoc.2009.03.007.

Tumor angiogenesis in melanoma.

Author information

1
Cutaneous Biology Research Center, Massachusetts General Hospital, Building 149, 13th Street, Charlestown, MA 02129, USA. alexander_marneros@yahoo.com

Abstract

A large number of clinical studies are being conducted to assess the effects of angiogenesis inhibitors in the treatment of patients who have metastatic melanoma. It has become increasingly clear that a therapeutic approach that combines angiogenesis inhibitors with cytotoxic agents or other treatment modalities is more likely to result in a clinical benefit for patients rather than antiangiogenesis treatments alone. However, a targeted treatment approach with antiangiogenic agents needs to be based on an in-depth understanding of the complex mechanisms involved in melanoma tumor angiogenesis.

PMID:
19464595
DOI:
10.1016/j.hoc.2009.03.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center